Chen YN, Wang PW, Tung SC, et al. - Researchers performed this case‐control study among 554 patients with type 2 diabetes, to determine if the Pro12Ala polymorphism results in the development of diabetic nephropathy (DN). Using real‐time polymerase chain reaction with TaqMan probe genotyping assay, the genotypes of Pro12Ala polymorphism of the peroxisome proliferator‐activated receptor gamma 2 gene were examined in all patients. In this study sample, the frequency of genotype Pro12Pro, Pro12Ala and Ala12Ala genotype were estimated to be 92.6%, 7.0%, 0.4%, and it was identified to be 90.4%, 8.9% and 0.7% in normal urinary albumin‐to‐creatinine ratio group, respectively. Significantly lower urinary albumin‐to‐creatinine ratio and better renal function were observed in Ala carriers (Pro12Ala + Ala12Ala) vs those with the genotype Pro12Pro. For the Ala12 allele, the odds ratio of albuminuria was estimated to be 0.428 following adjustment for age, gender and other confounders. Overall, it was concluded that significant protection against the development of albuminuria and DN was afforded by the peroxisome proliferator‐activated receptor gamma 2 Ala12 variant.